Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 studyAntoîne Italiano, Vincent Ribrag, Carlo Lucchesi et al.|The Lancet Oncology|2018Cited by 614
Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for childrenAndrew D.J. Pearson, Gilles Vassal, Kimberly Stegmaier et al.|European Journal of Cancer|2020Cited by 25